CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Caribou Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.46−0.01 (-1.26%)
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-1329.4%−1037.1 pts over 5 years
Net margin
-1327.4%−1049.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.7% | -7.0% | -2.0% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 429.5% | -79.0% | |
| Return on assets | – | – | -60.6% | |
| Current ratio | – | 1.96 | 5.71 | |
| Interest coverage | – | -1806.2× | – | |
| Capex to revenue | – | 2.6% | 12.2% | |
| Diluted shares | – | 9M | 93M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Caribou Biosciences generated $465.97M from operations and spent $26.43M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$465.97M
Used
$26.43M
Capital expenditure$26.43M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1327.4%
×Asset turnover0.05×
×Equity multiplier1.30×
=Return on equity, FY2025-79.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1327.4% | 0.05× | 1.30× | -79.0% |
| FY2024 | -1491.9% | 0.03× | 1.20× | -48.0% |
| FY2023 | -296.1% | 0.09× | 1.20× | -30.5% |
| FY2022 | -717.8% | 0.03× | 1.19× | -28.9% |
| FY2021 | -697.3% | 0.04× | 1.31× | -36.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$148.13M
- Cash generatingOperating cash flow above zero-$110.99M
- Return on assets improvedROA up on the prior year-34.5% → -47.3%
- Earnings backed by cashOperating cash flow above net income-$110.99M vs -$148.13M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.16 → 5.71
- No dilutionShare count did not rise90M → 93M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.02 → 0.04